Ratios

		vs industry	vs history
P/E(ttm)	51.80	AMRI's P/E(ttm) is ranked higher than 66% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 20.85 vs. AMRI: 51.80 )	AMRI' s 10-Year P/E(ttm) Range Min: 10.05   Max: 664 Current: 51.8 10.05 664
P/B	1.68	AMRI's P/B is ranked higher than 89% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 3.80 vs. AMRI: 1.68 )	AMRI' s 10-Year P/B Range Min: 0.28   Max: 17.96 Current: 1.68 0.28 17.96
P/S	1.45	AMRI's P/S is ranked higher than 94% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 6.90 vs. AMRI: 1.45 )	AMRI' s 10-Year P/S Range Min: 0.31   Max: 45.45 Current: 1.45 0.31 45.45
PFCF	19.10	AMRI's PFCF is ranked higher than 51% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 24.02 vs. AMRI: 19.10 )	AMRI' s 10-Year PFCF Range Min: 11.16   Max: 1757 Current: 19.1 11.16 1757
EV-to-EBIT	26.84	AMRI's EV-to-EBIT is ranked higher than 60% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 14.61 vs. AMRI: 26.84 )	AMRI' s 10-Year EV-to-EBIT Range Min: 5.8   Max: 333.6 Current: 26.84 5.8 333.6
Shiller P/E	86.1	AMRI's Shiller P/E is ranked lower than 68% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 4.20 vs. AMRI: 86.1 )	AMRI' s 10-Year Shiller P/E Range Min: 10.41   Max: 94.9 Current: 86.1 10.41 94.9

Valuation & Return

		vs industry	vs history
Price/Net Current Asset Value	6.7	AMRI's Price/Net Current Asset Value is ranked lower than 52% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 32.60 vs. AMRI: 6.7 )	AMRI' s 10-Year Price/Net Current Asset Value Range Min: 2.1   Max: 114.1 Current: 6.7 2.1 114.1
Price/Tangible Book	1.7	AMRI's Price/Tangible Book is ranked lower than 60% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 4.70 vs. AMRI: 1.7 )	AMRI' s 10-Year Price/Tangible Book Range Min: 0.4   Max: 8.7 Current: 1.7 0.4 8.7
Price/DCF (Projected)	1.7	AMRI's Price/DCF (Projected) is ranked higher than 85% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 2.00 vs. AMRI: 1.7 )	AMRI' s 10-Year Price/DCF (Projected) Range Min: 0.5   Max: 1.2 Current: 1.7 0.5 1.2
Price/Median PS Value	0.7	AMRI's Price/Median PS Value is ranked higher than 51% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 0.90 vs. AMRI: 0.7 )	AMRI' s 10-Year Price/Median PS Value Range Min: 0.2   Max: 21.2 Current: 0.7 0.2 21.2
Earnings Yield (Greenblatt)	3.70	AMRI's Earnings Yield (Greenblatt) is ranked higher than 72% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 8.00 vs. AMRI: 3.70 )	AMRI' s 10-Year Earnings Yield (Greenblatt) Range Min: 0.3   Max: 17.2 Current: 3.7 0.3 17.2
Forward Rate of Return (Yacktman)	-0.41	AMRI's Forward Rate of Return (Yacktman) is ranked higher than 84% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: -4.65 vs. AMRI: -0.41 )	AMRI' s 10-Year Forward Rate of Return (Yacktman) Range Min: -20.4   Max: 23.4 Current: -0.41 -20.4 23.4

Business Description

Albany Molecular Research, Inc is a Delaware corporation incorporated on June 20, 1991. It is a global contract research and manufacturing organization providing customers fully integrated drug discovery, development, and manufacturing services. The Company supplies a broad range of services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of Active Pharmaceutical Ingredients (API) and drug product for existing and experimental new drugs. With locations in the United States, Europe, and Asia, it maintains geographic proximity and flexible cost models. It has also historically leveraged its drug-discovery expertise to execute on several internal drug discovery programs, which have progressed to the development candidate stage and in some cases into Phase I clinical development. It has successfully partnered certain programs and is actively seeking to out-license its remaining programs to strategic partners for further development. The Company performs services including drug discovery, pharmaceutical development, and manufacturing of active ingredients and pharmaceutical intermediates for healthcare companies. The problem-solving abilities of its scientists can provide added value throughout the drug discovery, development and manufacturing process. The Company offers custom assay design and development services to clients in the pharmaceutical, biopharmaceutical and agrochemical industries who are starting from a unique target or who are supporting ongoing lead discovery programs. The Company's diverse offering of screening capabilities, coupled with access to its range of sample collections, give customers the essential tools to efficiently identify and optimize lead compounds. The Company's CADD services use sophisticated computational software and techniques to help identify novel hits or leads against selected therapeutic targets, as well as to support medicinal chemistry lead optimization programs. The Company has organized its activities into two distinct segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small Scale Manufacturing (DDS). The Company's LSM activities include pilot to commercial scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing and its remaining activities, including drug lead discovery, optimization, drug development, and small scale commercial manufacturing represent its DDS business segment. The manufacture, transportation and storage of its products are subject to certain international, Federal, state and local laws and regulations.
Company Website
SEC Reports

Industry:	Biotechnology
Compare:	NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:	AYM.Germany

» More Articles for AMRI

Headlines

Articles On GuruFocus.com

Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN Dec 05 2011

Personalized Checklist